Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 21:5:15441.
doi: 10.1038/srep15441.

Sustained suppression of viral replication in improving vitamin D serum concentrations in patients with chronic hepatitis B

En-Qiang Chen  1   2 , Lang Bai  1   2 , Tao-You Zhou  1   2 , Min Fe  1   2 , Dong-Mei Zhang  1   2 , Hong Tang  1   2
Affiliations

Sustained suppression of viral replication in improving vitamin D serum concentrations in patients with chronic hepatitis B

En-Qiang Chen et al. Sci Rep. .

Abstract

Recently, the role of vitamin D in chronic hepatitis B (CHB) has attracted a lot attention. In this study, 128 naïve CHB patients (91 with positive HBeAg, 37 with negative-HBeAg) were enrolled, and 128 volunteers without liver diseases were enrolled as controls. Compared to that of healthy controls, the mean level of 25(OH)D3 in CHB patients was significantly lower; and the percent of patients with sufficient 25(OH)D3 (≥20 ng/mL) was also significantly lower than that of healthy controls. Among those CHB patients, the level of 25(OH)D3 was negatively correlated with the serum HBV-DNA level. Additionally, the level of 25(OH)D3 was significantly lower in HBeAg-positive patients than that in HBeAg-negative patients. After the patients went through the long-term antiviral treatments, both the mean level of 25(OH)D3 and the percent of patients with sufficient 25(OH)D3 increased significantly. Additionally, patients who were HBeAg free after the treatment also had much higher 25(OH)D3 level than those with persistent positive HBeAg. All those data suggested that the low vitamin D serum level was dangerous for CHB patients, and the level of 25(OH)D3 was highly negatively correlated with HBV-DNA levels. Effective antiviral therapy might increase the level of vitamin D in CHB patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1. The distribution pattern of serum 25(OH)D3 in CHB patients and healthy controls.
(A) the mean level of serum 25(OH)D3; (B) the distribution interval of serum 25(OH)D3.
Figure 2
Figure 2. The distribution and correlation of serum 25(OH)D3 with serum Ca (A), P (B), ALP (C) and iPTH (D)
.
Figure 3
Figure 3. The distribution and correlation of serum 25(OH)D3 levels with demographic and biochemical parameters.
(A) the distribution of serum 25(OH)D3 based on gender (A) or family history of hepatitis B (B); the correlation of serum 25(OH)D3 level with patient age (C), BMI (D), and serum ALT levels (E).
Figure 4
Figure 4. The distribution and correlation of serum 25(OH)D3 levels with virological parameters.
(A) the distribution of serum 25(OH)D3 among different HBV genotypes (A) or HBeAg states (B); the correlation of serum 25(OH)D3 levels with patient serum HBV-DNA (C) and HBsAg levels (D).
Figure 5
Figure 5. serum 25(OH)D3 in patients before and after the long-term antiviral treatment.
(A) the mean level of serum 25(OH)D3 before and after treatment; (B) the distribution interval of serum 25(OH)D3 before and after treatment; (C) the mean level of serum 25(OH)D3 between patients with detectable and undetectable HBV DNA after treatment; (D) the distribution interval of serum 25(OH)D3 between patients with detectable and undetectable HBV DNA after treatment.
Figure 6
Figure 6. The mean level of serum 25(OH)D3 between patients with HBeAg free or not after treatment.
Figure 7
Figure 7. The relationship of serum 25(OH)D3 levels with seasonal changes before and after treatment.
See this image and copyright information in PMC

References

    1. Brandi M. L. & Minisola S. Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent. Curr Med Res Opin. 29, 1565–1572 (2013). - PubMed
    1. Moran-Auth Y., Penna-Martinez M., Shoghi F., Ramos-Lopez E. Badenhoop K. Vitamin D status and gene transcription in immune cells. J Steroid Biochem Mol Biol. 136, 83–85 (2013). - PubMed
    1. Miragliotta G. & Miragliotta L. Vitamin D and infectious diseases. Endocr Metab Immune Disord Drug Targets. 14, 267–271 (2014). - PubMed
    1. Chen E. Q., Shi Y. & Tang H. New insight of vitamin D in chronic liver diseases. Hepatobiliary Pancreat Dis Int. 13, 580–585 (2014). - PubMed
    1. Iruzubieta P., Teran A., Crespo J. & Fabrega E. Vitamin D deficiency in chronic liver disease.World J Hepatol. 6, 901–915 (2014). - PMC - PubMed

Publication types